• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.

作者信息

Ghobadi Armin, Landmann Jack H, Carter Alun, Cooper Matthew L, Selli Mehmet Emrah, Chang Jufang, Baker Matthew, Miller Christopher A, Ferraro Francesca, Chen David Y, Smith Amanda M, LaValle Taylor A, Duncavage Eric J, Chou Justin, Tam Victor, Benoun Joseph M, Nater Jenny, Scholler Nathalie, Milletti Francesca, Vezan Remus, Bot Adrian, Rossi John M, Singh Nathan

机构信息

Division of Oncology, Washington University School of Medicine, St Louis, MO.

The University of Texas Health Science Center at Houston, Houston, TX.

出版信息

Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705.

DOI:10.1182/bloodadvances.2022007705
PMID:35858291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9582720/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4db/9582720/918d148e6bbe/BLOODA_ADV-2022-007705-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4db/9582720/9bcbaafbacc1/BLOODA_ADV-2022-007705-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4db/9582720/918d148e6bbe/BLOODA_ADV-2022-007705-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4db/9582720/9bcbaafbacc1/BLOODA_ADV-2022-007705-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4db/9582720/918d148e6bbe/BLOODA_ADV-2022-007705-gr2.jpg

相似文献

1
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.发现一种使白血病细胞对靶向CD19免疫疗法产生抗性的新型基因组改变。
Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705.
2
Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing.通过深度基因组测序分析白血病对 CD19 靶向 CAR T 细胞治疗的耐药性。
Cancer Immunol Res. 2023 Jan 3;11(1):13-19. doi: 10.1158/2326-6066.CIR-22-0095.
3
Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.用于诊断和未来治疗目的的犬 CD19 抗体的产生和验证。
Vet Pathol. 2020 Mar;57(2):241-252. doi: 10.1177/0300985819900352. Epub 2020 Feb 21.
4
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.CD22 靶向 CAR T 细胞可诱导对 CD19 靶向 CAR 免疫疗法初治或耐药的 B-ALL 缓解。
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
5
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.双重靶向CD19和CD123可预防CD19导向免疫疗法后的抗原丢失复发。
J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.
6
A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.复发或难治性急性淋巴细胞白血病的CD19靶向免疫疗法综述
J Oncol Pharm Pract. 2018 Sep;24(6):453-467. doi: 10.1177/1078155217713363. Epub 2017 Jun 5.
7
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.针对 B 细胞急性淋巴细胞白血病的 CD3/CD19 双特异性和新型 CD3/CD19/CD20 三特异性抗体的临床前特征分析及比较：急性淋巴细胞白血病的靶向免疫治疗。
Front Med. 2022 Feb;16(1):139-149. doi: 10.1007/s11684-021-0835-8. Epub 2021 Aug 31.
8
How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.成人高危急性淋巴细胞白血病患者接受 CD19 靶向免疫治疗的策略
Blood. 2020 Mar 12;135(11):804-813. doi: 10.1182/blood.2019002132.
9
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.针对 CD19 的免疫疗法研究用于治疗急性淋巴细胞白血病。
Expert Opin Investig Drugs. 2021 Jul;30(7):773-784. doi: 10.1080/13543784.2021.1928074. Epub 2021 Jul 13.
10
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.CD20-CD19 双特异性 CAR T 细胞治疗 B 细胞恶性肿瘤。
Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.

引用本文的文献

1
The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies.共刺激结构域影响B细胞恶性肿瘤中CD19嵌合抗原受体T细胞耐药性的发展。
bioRxiv. 2025 Mar 4:2025.02.28.640707. doi: 10.1101/2025.02.28.640707.
2
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.INSPIRED 研讨会第 4B 部分：嵌合抗原受体 T 细胞相关研究——既定发现和未来重点。
Transplant Cell Ther. 2024 Feb;30(2):155-170. doi: 10.1016/j.jtct.2023.10.012. Epub 2023 Oct 18.

本文引用的文献

1
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.泽沃基奥仑赛注射液（KTE-X19）治疗复发或难治性成人 B 细胞急性淋巴细胞白血病：ZUMA-3 研究单臂、开放标签、多中心的 2 期结果。
Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4.
2
-Glycan Branching Is Required for Development of Mature B Cells.糖链分支对于成熟 B 细胞的发育是必需的。
J Immunol. 2020 Aug 1;205(3):630-636. doi: 10.4049/jimmunol.2000101. Epub 2020 Jun 26.
3
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
嵌合抗原受体（CAR）T 细胞治疗后肿瘤微环境中 CAR 和非 CAR T 细胞的激活。
JCI Insight. 2020 Jun 18;5(12):134612. doi: 10.1172/jci.insight.134612.
4
Mechanisms of resistance to CAR T cell therapies.CAR T 细胞疗法耐药机制。
Semin Cancer Biol. 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19.
5
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.CD19 细胞外结构域的精细表位作图促进设计。
Biochemistry. 2019 Dec 3;58(48):4869-4881. doi: 10.1021/acs.biochem.9b00808. Epub 2019 Nov 21.
6
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.肿瘤细胞 MHC-II 表达在癌症中的生物学后果
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. doi: 10.1158/1078-0432.CCR-18-3200. Epub 2018 Nov 21.
7
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.异基因移植后复发 AML 细胞的免疫逃逸。
N Engl J Med. 2018 Dec 13;379(24):2330-2341. doi: 10.1056/NEJMoa1808777. Epub 2018 Oct 31.
8
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.嵌合抗原受体 19 治疗急性淋巴细胞白血病中靶抗原丢失的遗传机制。
Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.
9
CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum.CD19 靶向免疫治疗后出现的改变导致错误折叠的蛋白质滞留在内质网中。
Mol Cell Biol. 2018 Oct 15;38(21). doi: 10.1128/MCB.00383-18. Print 2018 Nov 1.
10
Strelka2: fast and accurate calling of germline and somatic variants.Strelka2：快速准确地调用种系和体细胞变异。
Nat Methods. 2018 Aug;15(8):591-594. doi: 10.1038/s41592-018-0051-x. Epub 2018 Jul 16.